Summit Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Summit Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-3.7%
Buyback Yield
| Total Shareholder Yield | -3.7% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial
Dec 02Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?
Nov 08
Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market
Oct 04Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Sep 19Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)
Sep 09Summit Therapeutics May Have Further Upside From Here
Aug 03Summit Therapeutics Stock: Plunging Despite A Win?
May 31Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
May 06Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress
Jan 30Summit Therapeutics slips on plans to terminate study for lead candidate
Oct 04Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio
Aug 17Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M
Aug 11Summit to explore additional trial for its bacteria-induced colon infection drug
Jul 14Summit Therapeutics - Disappointing Data But Not An Outright Failure
Dec 23Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator
Jun 22Summit Therapeutics to join Russell 3000 Index
Jun 08Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if SMMT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SMMT's dividend payments have been increasing.
Dividend Yield vs Market
| Summit Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (SMMT) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (SMMT) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate SMMT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SMMT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate SMMT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SMMT has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 14:55 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Summit Therapeutics Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Waanders | Bryan Garnier & Co |
| Timothy Chiang | BTIG |
| Arlinda Lee | Canaccord Genuity |